Tetrahydrocannabinol||51.58 ADME||34.39 Bioavailability||34.39 Central Drug Research Institute||34.39 Bioequivalence||34.39 University of Arizona College of Pharmacy||34.39 Clopidogrel||34.39 Bisoprolol||34.39 Bromazepam||34.39 Biological half-life||25.79 Reboxetine||25.79 Bevirimat||25.79 Pefloxacin||25.79 Pharmaceutical sciences||25.79 Pharmacodynamics||25.79 Trifluoperazine||25.79 Plasma protein binding||25.79 Fospropofol||25.79 Proinsulin||17.19 Tocainide||17.19 Lipinski's Rule of Five||17.19 NONMEM||17.19 Patlak plot||17.19 First pass effect||17.19 Methylecgonidine||17.19 Flutoprazepam||17.19 Ro48-6791||17.19 Mechanism of action||17.19 Altretamine||17.19 Brotizolam||17.19 Microdosing||17.19 Distribution (pharmacology)||17.19 Drug interaction||17.19 Morphine-6-glucuronide||17.19 Free fraction||17.19 Oxicam||17.19 Lansoprazole||17.19 Pre-clinical development||17.19 Medicinal chemistry||17.19 Safety pharmacology||8.59 Pharmacometrics||8.59 Xenobiotica||8.59 Liposomal daunorubicin||8.59 Magnetic marker monitoring||8.59 Factor XIII deficiency||8.59 Australian Drug Evaluation Committee||8.59 Galenic formulation||8.59 Douwe Breimer||8.59 Fluocortin||8.59